Article Text

PDF
Letter
Management of submacular haemorrhage in age-related macular degeneration with intravitreal tenecteplase
  1. Ian L McAllister,
  2. Simon D Chen,
  3. Jignesh I Patel,
  4. Ben L Fleming,
  5. Dao-Yi Yu
  1. Lions Eye Institute, Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, Australia
  1. Correspondence to Ian L McAllister, Associate Professor, Lions Eye Institute, Centre for Ophthalmology and Visual Science, The University of Western Australia, Nedlands WA 6009, Australia; ianmcallister{at}lei.org.au

Statistics from Altmetric.com

Background and aims

We have previously reported that the thrombolytic tenecteplase (TNK) is able to penetrate the retina following an intravitreal injection of 50 μg with no evidence of retinal toxicity.1–3 The purpose of this report, which is the first in humans, is to assess its efficacy and safety in the management of patients with submacular haemorrhage (SMH) secondary to age-related macular degeneration.

Methods

Eight patients with a fresh SMH ranging from 3 to 14 days due to age-related macular degeneration and with a reduction in vision to less than or equal to 20/200 were enrolled for this study.

Following topical anaesthesia and 5% povodine iodine solution preparation, 50 μg of commercial TNK (Metalyse, Boehringer, Ingelheim, NSW, Australia) diluted with balanced salt solution …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.